Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
VSTM Stock Chart & Stats
$10.63
-$0.30(-4.59%)
At close: 4:00 PM EST
$10.63
-$0.30(-4.59%)
Day’s Range― - ―
52-Week Range$3.46 - $11.25
Previous CloseN/A
Volume547.29K
Average Volume (3M)2.81M
Market Cap
$800.65M
Enterprise Value$597.75M
Total Cash (Recent Filing)$137.71M
Total Debt (Recent Filing)$89.48M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 12, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.35
Shares Outstanding75,319,800
10 Day Avg. Volume2,916,083
30 Day Avg. Volume2,807,504
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-6.39
Price to Sales (P/S)18.46
P/FCF Ratio-1.76
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue44.68
Enterprise Value/Gross Profit53.07
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$15.50Price Target Upside45.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.98
Revenue Forecast (FY)$26.94M
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe IDMC’s recommendation to enroll additional patients across KRAS status supports the claim of positive progress in the RAMP 301 study.
EarningsThe company reported revenues of $11.2M for the quarter, beating consensus estimate of $5.7M.
Financial StabilityVSTM expects its cash runway to extend into the second half of 2026, providing financial stability.
Bears Say
Efficacy ConcernsThe objective response rate for VS-7375 has decreased from 52% to 41% compared to previous results, which may indicate a decline in efficacy over time.
Enrollment UncertaintyShares fell ~20% after the disclosure that the Independent Data Monitoring Committee (IDMC) recommended a modest, one-time enrollment increase of 29 patients in the confirmatory RAMP-301 study.
Stock VolatilityVSTM stock saw a surprising 20% drop on November 4 despite the strong topline revenues and continued progress on the clinical front.
Verastem News
VSTM FAQ
What was Verastem’s price range in the past 12 months?
Verastem lowest stock price was $3.46 and its highest was $11.24 in the past 12 months.
What is Verastem’s market cap?
Verastem’s market cap is $800.65M.
When is Verastem’s upcoming earnings report date?
Verastem’s upcoming earnings report date is Mar 12, 2026 which is in 102 days.
How were Verastem’s earnings last quarter?
Verastem released its earnings results on Nov 04, 2025. The company reported -$1.35 earnings per share for the quarter, missing the consensus estimate of -$0.617 by -$0.733.
Is Verastem overvalued?
According to Wall Street analysts Verastem’s price is currently Undervalued.
Does Verastem pay dividends?
Verastem does not currently pay dividends.
What is Verastem’s EPS estimate?
Verastem’s EPS estimate is -0.55.
How many shares outstanding does Verastem have?
Verastem has 75,319,800 shares outstanding.
What happened to Verastem’s price movement after its last earnings report?
Verastem reported an EPS of -$1.35 in its last earnings report, missing expectations of -$0.617. Following the earnings report the stock price went down -20.101%.
Which hedge fund is a major shareholder of Verastem?
Currently, no hedge funds are holding shares in VSTM
Verastem Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (45.81% Upside)
$15.50 (45.81% Upside)
Blogger Sentiment
Bullish
VSTM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 291.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
162.46%
12-Months-Change
Fundamentals
Return on Equity
-2888.70%
Trailing 12-Months
Asset Growth
39.94%
Trailing 12-Months
Company Description
Verastem
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
VSTM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted successful product launch and strong financial positioning, with significant revenue generation and advancements in clinical trials. However, continued expenses and the need for additional trial enrollment present challenges.View all VSTM earnings summariesVSTM Stock 12 Month Forecast
Average Price Target
$15.50
▲(45.81% Upside)
Technical Analysis
Cardiff Oncology
―
Mereo Biopharma Group Plc
―
Monopar Therapeutics Inc
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Ownership Overview
1.27% Insiders
7.32% Mutual Funds
9.95% Other Institutional Investors
71.53% Public Companies and
Individual Investors